As of May 2013, the date in which the 3rd month protocol biopsy was established, we have documented an incidence of sub-clinical acute rejections, including borderline and major rejections according to the Banff classification, of 52% (10/40 biopsies revealed acute cellular or humoral rejection and 11/40 had borderline injury). This number is unprecedented at the Institute because protocol biopsies were not previously obtained on the 3rd month.